Case Study: Launching an FDA OTC Antiperspirant With Health Canada Approval

Launching an antiperspirant deodorant in North America means working through two distinct regulatory regimes. In the United States, antiperspirants are FDA OTC drug products, which means Drug Facts panels, active ingredient compliance, and FDA registration. In Canada, antiperspirants fall under Health Canada's Natural Health Products or Drug regime depending on the active ingredient and claims, with separate documentation requirements.

A natural body care brand came to Petra Lab-X wanting to launch an aluminum-based antiperspirant cream alongside their existing aluminum-free deodorant line. They had no prior FDA OTC experience and were trying to clear both US and Canadian markets simultaneously. Here's how we got them launched.

The Challenge

The brand had built their existing aluminum-free natural deodorant line around clean-beauty positioning. The new antiperspirant — using aluminum chlorohydrate as the active — was a regulatory category jump. Three problems:

FDA OTC compliance. The active ingredient had to meet FDA's antiperspirant monograph specifications. The product had to carry a Drug Facts panel. The manufacturing facility itself had to comply with FDA's drug Good Manufacturing Practice (cGMP) standards beyond the cosmetic GMP standards their existing line was built under.

Health Canada parallel approval. Canadian antiperspirants fall under Drug regulations with their own DIN application and specific claim language requirements that don't perfectly align with US FDA labeling.

Brand consistency. The new product had to feel and behave like their natural line — same packaging system, same sensory profile, same brand voice — despite being a fundamentally different category internally.

What We Did

Phase one was regulatory mapping. We outlined the parallel FDA and Health Canada submission requirements and what specifications the product would need to hit for both. The active ingredient (aluminum chlorohydrate) was simpler than alternatives because it's well-established in both monographs.

Phase two was formulation development. The cream format requested by the brand needed a system that suspended the active uniformly without separation, applied smoothly without rolling or balling, and dried to a non-tacky finish. We ran three prototype rounds before sign-off.

Phase three was manufacturing process documentation for FDA cGMP. Our facility runs cosmetic GMP (ISO 22716) as our baseline, and we run cGMP-equivalent processes for OTC drug products. Process validation, batch record templates, and quality control sampling protocols were documented and submitted as part of the regulatory package.

Phase four was Drug Facts panel preparation and label review against both FDA and Health Canada requirements. Bilingual labeling for Canadian distribution required additional layout work.

Phase five was first production with full QC sampling at multiple points in the run, batch records archived per cGMP requirements.

The Outcome

The brand launched the antiperspirant cream in both US and Canada within their target Q1 launch window. The product is now part of their core line and sits as their highest-margin SKU.

Specific outcomes:

• FDA OTC drug product compliance documented and validated

• Health Canada DIN approval obtained

• Production scaled from initial 8,000 unit run to recurring monthly production within four months

• Bilingual Drug Facts and Canadian-required labeling implemented at production

• Brand subsequently launched a roll-on format antiperspirant 18 months later, building on the regulatory foundation

Why This Worked

OTC drug products have a higher regulatory floor than cosmetics, and most contract manufacturers that operate in cosmetic GMP only can't pick up an OTC project without significant facility and process work. The work of regulatory and operational readiness for OTC drug products has to happen ahead of the first project, not during it.

Petra's deodorant manufacturing program handles natural deodorants, aluminum-based antiperspirants, and the regulatory work that goes with each.

Frequently Asked Questions

Does Petra hold FDA cGMP for OTC drug products?

Yes. Our facility runs ISO 22716 cosmetic GMP as the baseline and operates cGMP-equivalent processes for OTC drug products including antiperspirants and acne treatments.

Can you handle Drug Facts panel preparation?

Yes. Drug Facts panel preparation, active ingredient claim language, and warnings statements are handled in-house as part of the regulatory package.

What's the timeline difference between a cosmetic deodorant and an FDA OTC antiperspirant?

OTC adds typically 4-8 weeks to the timeline depending on regulatory documentation completeness and whether the active is a familiar monograph ingredient or a novel application.

Do you handle Health Canada DIN applications?

Yes. Health Canada DIN applications, NPN applications for natural health product positioned products, and bilingual labeling for Canadian distribution are routine.

Launching a Regulated Personal Care Product?

If you're entering FDA OTC territory — antiperspirants, sunscreens, anti-acne, anti-dandruff shampoos — the regulatory path is the project, not an afterthought. We'd be happy to talk through what your specific category requires.

Submit a project inquiry →